These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 28596090)

  • 1. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
    Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S
    Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Immunogenicity and Protective Efficacy of a
    Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
    mSphere; 2019 May; 4(3):. PubMed ID: 31043512
    [No Abstract]   [Full Text] [Related]  

  • 4. First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults.
    Hutter JN; Robben PM; Lee C; Hamer M; Moon JE; Merino K; Zhu L; Galli H; Quinn X; Brown DR; Duncan E; Bolton J; Zou X; Angov E; Lanar DE; Rao M; Matyas GR; Beck Z; Bergmann-Leitner E; Soisson LA; Waters NC; Ngauy V; Regules J; Dutta S
    Vaccine; 2022 Sep; 40(40):5781-5790. PubMed ID: 36055874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin.
    Martin ML; Bitzer AA; Schrader A; Bergmann-Leitner ES; Soto K; Zou X; Beck Z; Matyas GR; Dutta S
    Malar J; 2019 Nov; 18(1):377. PubMed ID: 31775762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.
    Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR
    Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.
    Pirahmadi S; Zakeri S; Mehrizi AA; Djadid ND; Raz AA; Sani JJ
    Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936155
    [No Abstract]   [Full Text] [Related]  

  • 8. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.
    Tewari K; Flynn BJ; Boscardin SB; Kastenmueller K; Salazar AM; Anderson CA; Soundarapandian V; Ahumada A; Keler T; Hoffman SL; Nussenzweig MC; Steinman RM; Seder RA
    Vaccine; 2010 Oct; 28(45):7256-66. PubMed ID: 20846528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.
    Beck Z; Torres OB; Matyas GR; Lanar DE; Alving CR
    J Control Release; 2018 Apr; 275():12-19. PubMed ID: 29432824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
    Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
    Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
    Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
    PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.
    Pichyangkul S; Kum-Arb U; Yongvanitchit K; Limsalakpetch A; Gettayacamin M; Lanar DE; Ware LA; Stewart VA; Heppner DG; Mettens P; Cohen JD; Ballou WR; Fukuda MM
    Infect Immun; 2008 Jan; 76(1):229-38. PubMed ID: 17954725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.
    Ober Shepherd BL; Scott PT; Hutter JN; Lee C; McCauley MD; Guzman I; Bryant C; McGuire S; Kennedy J; Chen WH; Hajduczki A; Mdluli T; Valencia-Ruiz A; Amare MF; Matyas GR; Rao M; Rolland M; Mascola JR; De Rosa SC; McElrath MJ; Montefiori DC; Serebryannyy L; McDermott AB; Peel SA; Collins ND; Joyce MG; Robb ML; Michael NL; Vasan S; Modjarrad K;
    Lancet Microbe; 2024 Jun; 5(6):e581-e593. PubMed ID: 38761816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge.
    Friedman-Klabanoff DJ; Berry AA; Travassos MA; Shriver M; Cox C; Butts J; Lundeen JS; Strauss KA; Joshi S; Shrestha B; Mo AX; Nomicos EYH; Deye GA; Regules JA; Bergmann-Leitner ES; Pasetti MF; Laurens MB
    J Infect Dis; 2024 Jun; 229(6):1883-1893. PubMed ID: 38330357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
    Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
    Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
    Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
    PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
    Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
    Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
    Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
    Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.